---
title: "Sino Biopharm says China approves zongertinib for first-line HER2-mutant NSCLC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287221446.md"
description: "Sino Biopharmaceutical announced that China's NMPA has approved zongertinib, an oral HER2 tyrosine kinase inhibitor, for first-line treatment of adults with unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer. The approval is based on Phase 1b Beamion-LUNG 1 data showing a 76% confirmed objective response rate and a median progression-free survival of 14.4 months."
datetime: "2026-05-21T12:35:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287221446.md)
  - [en](https://longbridge.com/en/news/287221446.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287221446.md)
---

# Sino Biopharm says China approves zongertinib for first-line HER2-mutant NSCLC

-   Sino Biopharmaceutical said China’s NMPA cleared zongertinib, an oral HER2 tyrosine kinase inhibitor it co-promotes with Boehringer Ingelheim, for first-line treatment of adults with unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer. \* The conditional approval was supported by Phase 1b Beamion-LUNG 1 data showing a 76% confirmed objective response rate, with median progression-free survival of 14.4 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260521-12167385), on May 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline](https://longbridge.com/en/news/286328735.md)
- [TransThera reports promising tinengotinib results in advanced solid tumors](https://longbridge.com/en/news/286670762.md)
- [Kickstarter just killed its new mature content rules](https://longbridge.com/en/news/286954763.md)
- [Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer | AZN Stock News](https://longbridge.com/en/news/286621973.md)
- [Grown Up Group Sets June 2026 AGM to Approve Results and Share Mandate](https://longbridge.com/en/news/286990715.md)